High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience

Overview

Journal Euroasian J Hepatogastroenterol

Specialty Gastroenterology

Date 2024 Jul 18

PMID 39022196

Authors

Rajesh Upadhyay

Navin K Soni

Ashwin A Kotamkar

Azra Naseem

Aaditi Phadke

Shreshth Nayar

Shailesh Pallewar

Parvan Shetty

Ashish Mungantiwar

Sunil Jaiswal

Amit Qamra

Affiliations

Soon will be listed here.

Abstract

How To Cite This Article: Upadhyay R, Soni NK, Kotamkar AA, . High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepato-Gastroenterol 2024;14(1):86-91.

References

Sperber A, Bangdiwala S, Drossman D, Ghoshal U, Simren M, Tack J . Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2020; 160(1):99-114.e3. DOI: 10.1053/j.gastro.2020.04.014. View

Kalaitzakis E, Bjornsson E . A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag. 2008; 3(4):653-63. PMC: 2374928. View

Cicala M, Emerenziani S, Guarino M, Ribolsi M . Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013; 19(39):6529-35. PMC: 3801364. DOI: 10.3748/wjg.v19.i39.6529. View

Chowdhury S, George G, Ramakrishna K, Ramadass B, Pugazhendhi S, Mechenro J . Prevalence and factors associated with gastroesophageal reflux disease in southern India: A community-based study. Indian J Gastroenterol. 2019; 38(1):77-82. DOI: 10.1007/s12664-018-00931-6. View

Al Ghadeer H, Alabbad Z, Alshaikh S, Ahmed S, Bu-Khamseen A, Alhashem A . Prevalence of Gastroesophageal Reflux Disease and Associated Risk Factors in the Eastern Region, Saudi Arabia. Cureus. 2021; 13(11):e19599. PMC: 8671076. DOI: 10.7759/cureus.19599. View

Jungnickel P . Pantoprazole: a new proton pump inhibitor. Clin Ther. 2000; 22(11):1268-93. DOI: 10.1016/s0149-2918(00)83025-8. View

Rai S, Kulkarni A, Ghoshal U . Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021; 40(2):209-219. DOI: 10.1007/s12664-020-01104-0. View

Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G . Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne). 2021; 8:765061. PMC: 8591082. DOI: 10.3389/fmed.2021.765061. View

Strand D, Kim D, Peura D . 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2016; 11(1):27-37. PMC: 5221858. DOI: 10.5009/gnl15502. View

10.

Bhatia S, Pareek K, Kumar A, Upadhyay R, Tiwaskar M, Jain A . API-ISG Consensus Guidelines for Management of Gastrooesophageal Reflux Disease. J Assoc Physicians India. 2020; 68(10):69-80. View

11.

Srivastava K, Arora A, Kataria A, Cappelleri J, Sadosky A, Peterson A . Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013; 7:419-34. PMC: 3669002. DOI: 10.2147/PPA.S44646. View

12.

Ang D, How C, Ang T . Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. Singapore Med J. 2016; 57(10):546-551. PMC: 5075954. DOI: 10.11622/smedj.2016167. View

13.

Yadlapati R, Gyawali C, Pandolfino J . AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022; 20(5):984-994.e1. PMC: 9838103. DOI: 10.1016/j.cgh.2022.01.025. View

14.

Laufs U, Rettig-Ewen V, Bohm M . Strategies to improve drug adherence. Eur Heart J. 2010; 32(3):264-8. DOI: 10.1093/eurheartj/ehq297. View

15.

Ness-Jensen E, Hveem K, El-Serag H, Lagergren J . Lifestyle Intervention in Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol. 2015; 14(2):175-82.e1-3. PMC: 4636482. DOI: 10.1016/j.cgh.2015.04.176. View

16.

Clarrett D, Hachem C . Gastroesophageal Reflux Disease (GERD). Mo Med. 2018; 115(3):214-218. PMC: 6140167. View

17.

Sandhu D, Fass R . Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver. 2017; 12(1):7-16. PMC: 5753679. DOI: 10.5009/gnl16615. View

18.

Chen W, Chang W, Tsai Y, Cheng H, Lu C, Sheu B . Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am J Gastroenterol. 2009; 105(5):1046-52. DOI: 10.1038/ajg.2009.632. View

19.

Coleman C, Limone B, Sobieraj D, Lee S, Roberts M, Kaur R . Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012; 18(7):527-39. PMC: 10438207. DOI: 10.18553/jmcp.2012.18.7.527. View

20.

Matuz M, Benko R, Engi Z, Schvab K, Doro P, Viola R . Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol. 2020; 11:552102. PMC: 7506043. DOI: 10.3389/fphar.2020.552102. View